Centers for Disease Control and Prevention, Three Waves of Opioid Overdose Deaths, available at <cdc.gov/opioids/basics/epidemic.htm> (last visited Dec. 6, 2021).+(last+visited+Dec.+6,+2021).>Google Scholar

Ahmad, F.B., Rossen, L.M., and Sutton, P., “Provisional Drug Overdose Death Count, National Center for Health Statistics,” Nov. 7, 2021, available at <cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#data-tables> (last visited Dec. 6, 2021).+(last+visited+Dec.+6,+2021).>Google Scholar

See generally Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse, National Academies of Sciences, Engineering, and Medicine, Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use (R.J. Bonnie, M.A. Ford, and J.K. Phillips, eds., Washington, D.C.: The National Academies Press, 2017).Google Scholar

See generally Keefe, P.R., Empire of Pain: The Secret History of the Sackler Dynasty (New York: Doubleday, 2021).Google Scholar

See Rothstein, M.A., “Ethical Responsibilities of Physicians in the Opioid Crisis,” Journal of Law, Medicine & Ethics 45, no. 2 (2017): 682–687.CrossRefGoogle Scholar

See Hoffman, J., “CVS, Walgreens and Walmart Fueled Opioid Crisis, Jury Finds,” The New York Times, Nov. 23, 2021, available at <https://www.nytimes.com/2021/11/23/health/walmart-cvs-opioid-lawsuit-verdict.html> (last visited Dec. 9, 2021).+(last+visited+Dec.+9,+2021).>Google Scholar

See Weedn, V.W. et al., “Fentanyl-Related Substance Scheduling as an Effective Drug Control Strategy,” Journal of Forensic Sciences 66 (2021): 1186–1200, doi: 10.1111/1556-4029.14712.CrossRefGoogle ScholarPubMed

Madras, B.K. et al., Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System, National Academy of Medicine Discussion Paper (April 27, 2020), available at <https://www.rcorp-ta.org/sites/default/files/2020-06/Improving-Access-to-Evidence-Based-Medical-Treatment-for-OUD_FINAL.pdf> (last visited Dec. 9, 2021).CrossRef+(last+visited+Dec.+9,+2021).>Google Scholar

See Case, A. and Deaton, A., “Rising Morbidity and Mortality among White Non-Hispanic Americans in the 21st Century,” Proceedings of the National Academy of Sciences USA 112, no. 49 (2015): 15078–15083.Google Scholar

Although beyond the scope of this article, another possible source of related litigation is an action against a pharmacy for failure to fill an opioid prescription in violation of Title III of the Americans with Disabilities Act and Section 504 of the Rehabilitation Act. See Fuog v. CVS Pharmacy, Inc., 2021 WL 4355401 (D.R.I. 2021).Google Scholar

Lanser, P. and Gesell, S., “Pain Management: The Fifth Vital Sign,” Healthcare Benchmarks 8, no. 6 (2001): 68–70.Google ScholarPubMed

See Keefe, P.R., supra note 4, at 194.Google Scholar

Id. at 195.Google Scholar

See Van Zee, A., “The Promotion of OxyContin: Commercial Triumph, Public Health Tragedy,” American Journal of Public Health 99, no. 2 (1999): 221–227.CrossRefGoogle Scholar

Levy, B. et al., “Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007-2012,” American Journal of Preventive Medicine 49, no. 3 (2015): 409–413.CrossRefGoogle ScholarPubMed

Paulozzi, L.J., Mack, K.A., and Hockenberry, J.M., “Vital Signs: Variation among States in Prescribing of Opioid Pain Relievers and Benzodiazepines — United States, 2012,” Morbidity and Mortality Weekly Report 63 (2014): 563–568. See also Centers for Disease Control and Prevention, U.S. Opioid Dispensing Rate Maps, available at <https://www.cdc.gov/drugoverdose/rxrate-maps/index.html> (last visited Dec. 7, 2021).Google ScholarPubMed

Centers for Disease Control and Prevention, Annual Surveillance Report of Drug-Related Risks and Outcomes: United States, 2017, at 9 (2017).Google Scholar

Han, B. et al., “Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health,” Annals of Internal Medicine 167, no. 5 (2017): 293–302.CrossRefGoogle ScholarPubMed

U.S. Department of Health and Human Services, Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (2016), HHS Publication SMA 16-4984, NSDUH Series H-51 (Rockville, MD: SAMHSA).Google Scholar

Dowell, D., Haegerich, T.M., and Chou, R., “CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016,” Morbidity and Mortality Weekly Reports Recommendation Reports 65, no. 1 (2016): 1-49.Google Scholar

Id. at 2.Google Scholar

Rothstein, M.A. and Irzyk, J., “The Opioid Crackdown Leaves Chronic Pain Patients in Limbo,” The Hill, Nov. 29, 2021, available at <https://thehill.com/opinion/healthcare/583332-the-opioid-crackdown-leaves-chronic-pain-patients-in-limbo> (last accessed Dec. 7, 2021).Google Scholar

American Medical Association, Comments on the CDC Guideline for Prescribing Opioids for Chronic Pain (June 16, 2020), available at < https://searchlf.ama-assn.org/finder/letter/search/opioid/relevant/1/> (last visited Dec. 7, 2021).+(last+visited+Dec.+7,+2021).>Google Scholar

. D. Dowell et al., supra note 20, at 16.Google Scholar

Volkow, See N., Benveniste, H., and McLellan, A.T., “Use and Misuse of Opioids in Chronic Pain,” Annual Review of Medicine 69 (2018): 451–465.CrossRefGoogle ScholarPubMed

Nadeau, S.E., Wu, J.K., and Lawhern, R.A., “Opioids and Chronic Pain: An Analytical Review of the Clinical Evidence,” Frontiers in Pain Research 2 (2021), art. 721357, doi: 10.3389/fpain.2021.721357.CrossRefGoogle ScholarPubMed

D. Dowell et al., supra note 20, at 16.Google Scholar

Kroenke, K. and Cheville, A., “Management of Chronic Pain in the Aftermath of the Opioid Backlash,” Journal of the American Medical Association 317, no. 23 (2017): 2365–2366, 2366.CrossRefGoogle ScholarPubMed

Nadeau, Wu, and Lawhern, supra note 26, citing Rose, M.E., “Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs. Facts,” Pain Medicine 19 (2018): 793–807, doi: 10.1093/pm/pnx048.CrossRefGoogle ScholarPubMed

National Conference of State Legislatures, Prescribing Policies: States Confront Opioid Overdose Epidemic (June 30, 2019), available at <https://www.ncsl.org/research/health/prescribing-policies-states-confront-opioid-overdose-epidemic.aspx> (last visited Nov. 11, 2021). See also Guevremont, N., Barnes, M., and Haupt, C.E., “Physician Autonomy and the Opioid Crisis,” Journal of Law, Medicine & Ethics 46, no. 1 (2018): 203–219; M.E. Schatman and H. Shapiro, “Damaging State Legislation Regarding Opioids: The Need to Scrutinize Sources of Inaccurate Information Provided to Lawmakers,” Journal of Pain Research 12 (2019): 3049-3053, doi: 10.2147/JPR.S235366.CrossRefGoogle ScholarPubMed

Enzinger, A.C. et al., “US Trends in Opioid Access among Patients with Poor Prognosis Cancer Near the End-of-Life,” Journal of Clinical Oncology 39, no. 26 (2021): 2948–2958.CrossRefGoogle ScholarPubMed

Rieder, T.N., “Is Nonconsensual Tapering of High-Dose Opioid Therapy Justifiable?” AMA Journal of Ethics 22, no. 8 (2020): E651–657.Google ScholarPubMed

D. Dowell et al., supra note 20, at 26.Google Scholar

Agnoli, A. et al., “Association of Dose Tapering with Overdose or Mental Health Crisis among Patients Prescribed Long-Term Opioids,” Journal of the American Medical Association (August 3, 2021), doi: 10.1001/jama.2021.11118.CrossRefGoogle Scholar

Oquendo, M.A. and Volkow, N.D., “Suicide: A Silent Contributor to Opioid-Overdose Deaths,” New England Journal of Medicine 378, no. 17 (2018): 1567–1569.CrossRefGoogle ScholarPubMed

The facts of the case have been drawn from A. Joseph, “Her Husband Died by Suicide. She Sued His Pain Doctors — A Rare Challenge Over an Opioid Reduction,” STAT, Nov. 22, 2021, available at <https://www.statnews.com/2021/11/22/her-husband-died-by-suicide-she-sued-his-pain-doctors-a-rare-challenge-over-an-opioid-dose-reduction/?utm_content=buffera5bdd&utm_medium=social&utm_source=twitter&utm_campaign=twitter_organic> (last visited Nov. 24, 2021), and Slone v. Commonwealth Pain & Spine (Jefferson Cty. Cir. Ct., Aug. 27, 2021), 2021 Ky. Trial Ct. Rev. LEXIS 37, available at <http://plus.lexis.com/api/permalink/9064c0ff-dfcc-4b51-9bca-d0c6f9a7ba29/?context=1530671> (Plaintiff’s Response in Opposition to Defendants’ Motion for Summary Judgment).+(last+visited+Nov.+24,+2021),+and+Slone+v.+Commonwealth+Pain+&+Spine+(Jefferson+Cty.+Cir.+Ct.,+Aug.+27,+2021),+2021+Ky.+Trial+Ct.+Rev.+LEXIS+37,+available+at++(Plaintiff’s+Response+in+Opposition+to+Defendants’+Motion+for+Summary+Judgment).>Google Scholar

D. Dowell et al., supra note 20, at 16.Google Scholar

Slone v. Commonwealth Pain & Spine (Jefferson Cty. Cir. Ct., Aug. 27, 2021), 2021 Ky. Trial Ct. Rev. LEXIS 37, available at <http://plus.lexis.com/api/permalink/9064c0ff-dfcc-4b51-9bca-d0c6f9a7ba29/?context=1530671> (last visited January 4, 2022).+(last+visited+January+4,+2022).>Google Scholar

Interview by Mark A. Rothstein with Hans Poppe, Dec. 2, 2021.Google Scholar

Keeton, W. Page et al., Prosser and Keeton on the Law of Torts § 30 (5th ed. 1984), at 164-165.Google Scholar

See id. at §§ 126-127.Google Scholar

American Law Institute, Restatement (Third) of the Law of Torts § 3 (2010).Google Scholar

W. Page Keeton et al., supra note 40, at 164.Google Scholar

Id. at 187.Google Scholar

American Medical Association, Code of Medical Ethics of the American Medical Association (2017), at 7.Google Scholar

See De Ruddere, L. and Craig, K., “Understanding Stigma and Chronic Pain: A State-of-the-Art Review,” Pain 157, no. 8 (2016): 1607–1610; Y. Olsen and J.M. Sharfstein, “Confronting the Stigma of Opioid Use Disorder — and Its Treatment,” Journal of the American Medical Association 311, no. 4 (2014): 1393-1394.CrossRefGoogle ScholarPubMed

See Collen, M., “Opioid Contracts and Random Drug Testing for People with Chronic Pain — Think Twice,” Journal of Law, Medicine & Ethics 40, no. 4 (2009): 841–845.CrossRefGoogle Scholar

The CDC Guideline labels its recommendation for initial and periodic urine drug testing as a category B recommendation, meaning that “individual decision making” by the clinician is required. See D. Dowell et al., supra note 20, at 16, recommendation 10. Drug testing, however, is often an across-the-board policy of institutions or clinicians.Google Scholar

See Rapoport, A.B. and Rowley, C.F., “Stretching the Scope — Becoming Frontline Addiction-Medicine Providers,” New England Journal of Medicine 377, no. 8 (2017): 705–707, 706 (“At some point, it became culturally acceptable to treat all conditions in a patient except addiction.”).CrossRefGoogle ScholarPubMed

See Singing River Health System v. Vermilyea, 242 So.3d 74 (Miss. 2018); Komlodi v. Picciano, 89 A.3d 1234 (N.J. 2014).CrossRefGoogle Scholar

966 N.W.2d 460 (Mich. Ct. App. 2020).Google Scholar

Other elements in the case against the physician, such as prescribing and injecting a relative without a sufficient medical evaluation, might have justified sanctions, but relying on the CDC Guideline as the standard of care is a troubling precedent.Google Scholar

American Law Institute, Restatement (Third) of the Law of Torts § 26, comment l (2010).Google Scholar

The Restatement (Third) of the Law of Torts uses neither the term “legal cause” nor “proximate cause,” instead using “scope of liability” to address the issue of how far liability should extend as a matter of policy. See id. at ch. 6.Google Scholar

Rollins v. Wackenhut Servs., 703 F.3d 122 (D.C. Cir. 2012); Riesbeck Drug Co. v. Wray, 39 N.E.2d 776 (Ind. Ct. App. 1942); Sindler v. Litman, 887 A.2d 97 (Md. Ct. App. 2005); Wickersham v. Ford Motor Co., 853 S.E.2d 329 (S.C. 2020); Cotton v. Wilson, 576 S.W.3d 626 (Tenn. 2019). See generally Long, A.B., “Abolishing the Suicide Rule,” Northwestern University Law Review 113, no. 4 (2019): 767–824.Google Scholar

Parton v. Jeans, 2019 WL 6608750 (Ariz. Ct. App. 2019); Porter v. Murphy, 792 A.2d 1009 (Del. Super. Ct. 2009); Crumpton v. Walgreen Co., 871 N.E.2d 905 (Ill. 2007); Bertrand v. Air Logistics, Inc., 820 So. 2d 1228 (La. Ct. App. 2002); Truddle v. Baptist Mem’l Hosp.-Desoto, Inc., 150 So. 3d 692 (Miss. 2014); Lenoci v. Leonard, 21 A.3d 694 (Vt. 2011); Arsnow v. Red Top Cab Co., 292 P. 436 (Wash. 1930); McMahon v. St. Croix Falls School Dist., 596 N.W.2d 875 (Wis. Ct. App. 1999); R.D. v. W.H., 875 P.2d 26 (Wyo. 1994). See generally Restatement (Second) of the Law of Torts § 445 (1958). This exception has been criticized as being medically and legally defective and stigmatizing mental illness with rhetoric from the Middle Ages. See Long, supra note 55, at 811-812.Google Scholar

Gilmore v. Shell Oil Co., 613 So.2d 1272 (Ala. 1993); Joseph v. State, 26 P.3d 459 (Alaska 2001); Meils v. Northwestern Bell Tel. Co., 355 N.W.2d 710 (Minn. 1984); McPeake v. Cannon, 553 A.2d 439 (Pa. Super. Ct. 1989. (Worsham v. Nix, 83 P.3d 879 (Okla. Civ. App. 2003); Moats v. Preston County Comm’n, 521 S.E.2d 180 (W. Va. 1999).Google Scholar

Kockelman v. Segal, 61 Cal. App.4th 491 (Cal. App. 1998); Lee v. Corregedore, 925 P.2d 324 (Haw. 1996); Costigan v. Plets, 2011 WL 6376016 (Mich. Ct. App. 2011).Google Scholar

Wyke v. Polk County School Board, 129 F.3d 560 (11th Cir. 1997).Google Scholar

Schiezler v. Ferrum College, 236 F. Supp. 2d 602 (W.D. Va. 2002).Google Scholar

Patton v. Bickford, 529 S.W.3d 717 (Ky. 2016).Google Scholar

See, e.g., Meir v. Ross General Hospital, 445 P.2d 519 (Cal. 1968); Wozniak v. Lipoff, 750 P.2d 971 (Kan. 1988); Champagne v. United States, 513 N.W.2d 75 (N.D. 1994).Google Scholar

Kivland v. Columbia Orthopaedic Group LLP, 331 S.W.3d 299 (Mo. 2011).Google Scholar

White v. Lawrence, 975 S.W.2d 525 (Tenn. 1998).Google Scholar

692 A.2d 1266 (Conn. 1997).Google Scholar

Id., at 1270.Google Scholar

Slone v. Commonwealth Pain & Spine, supra note 38 (Instruction No. 6).Google Scholar

See Centers for Disease Control and Prevention, supra note 17.Google Scholar

National Center for Health Statistics, Centers for Disease Control and Prevention, Drug Overdose Deaths in US Top 100,000 Annually (Nov. 17, 2021), available at <https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/2021117.htm> (last visited Dec. 12, 2021).+(last+visited+Dec.+12,+2021).>Google Scholar

See Oquendo and Volkow, supra note 35.Google Scholar

See, e.g., Koon v. Walden, 539 S.W.3d 752 (Mo. Ct. App. 2017) (affirming multi-million-dollar damage award for overprescribing opioids, which resulted in the plaintiff’s addiction). See also Slat, S. et al., “Opioid Policy and Chronic Pain Treatment Access Experiences: A Multi-Stakeholder Qualitative Analysis and Conceptual Model,” Journal of Pain Research 14 (2021): 1161–1169, (“fear of litigation as justification for decreasing opioid prescribing”).CrossRefGoogle ScholarPubMed